Pluristem Therapeutics Inc. (NASDAQ:PSTI) has been assigned a $3.00 price target by Maxim Group in a report released on Wednesday. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective would suggest a potential upside of 94.81% from the stock’s previous close.
Other equities research analysts also recently issued reports about the company. FBR & Co reiterated a “buy” rating on shares of Pluristem Therapeutics in a report on Monday, July 11th. HC Wainwright reiterated a “buy” rating and issued a $3.50 price target on shares of Pluristem Therapeutics in a report on Tuesday, July 19th. Finally, Zacks Investment Research downgraded Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 5th.
Pluristem Therapeutics (NASDAQ:PSTI) traded up 1.99% on Wednesday, hitting $1.54. The stock had a trading volume of 50,745 shares. The company’s market cap is $124.77 million. The stock has a 50-day moving average of $1.53 and a 200-day moving average of $1.53. Pluristem Therapeutics has a one year low of $0.71 and a one year high of $1.85.
A hedge fund recently raised its stake in Pluristem Therapeutics stock. Jane Street Group LLC boosted its stake in shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 33.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 104,754 shares of the company’s stock after buying an additional 26,038 shares during the period. Jane Street Group LLC owned approximately 0.13% of Pluristem Therapeutics worth $139,000 at the end of the most recent reporting period. 3.75% of the stock is currently owned by institutional investors and hedge funds.
About Pluristem Therapeutics